Integrating GLP-1 Receptor Agonists Into Dermatology Practice: Safety and Monitoring Strategies

Area of Science:

• Dermatology
• Endocrinology
• Pharmacology

Background:

• Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for type 2 diabetes and obesity.
• Newer formulations and triple agonists show significant weight reduction.
• Growing patient use necessitates understanding of dermatologic implications.

Purpose of the Study:

• To review the safety profile of GLP-1RAs with a focus on dermatologic adverse events.
• To highlight interdisciplinary monitoring strategies for patients on GLP-1RA therapy.
• To inform dermatologists about potential side effects and management.

Main Methods:

• Review of current evidence on GLP-1RA safety and adverse effects.
• Emphasis on dermatologic manifestations and systemic complications.
• Discussion of monitoring, counseling, and multidisciplinary care.

Main Results:

• Common adverse effects include GI intolerance, nutritional deficiencies, and lean body mass loss.
• Dermatologic events encompass alopecia, eruptions, and facial volume loss ('Ozempic face').
• Potential associations with ophthalmologic, skeletal, and body composition changes noted.

Conclusions:

• GLP-1RAs present a spectrum of dermatologic and systemic side effects requiring monitoring.
• A multidisciplinary approach is crucial for optimizing patient safety and therapeutic benefits.
• Dermatologists need to be aware of contraindications, screening, and counseling for GLP-1RA users.